Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating … (NCT00310128) | Clinical Trial Compass
WithdrawnPhase 2
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Stopped: Drug supply unavailable
0Started 2006-02
Plain-language summary
RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them without harming normal cells. Giving more than one drug (combination chemotherapy) together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically or cytologically documented B-cell non-Hodgkin's lymphoma, including any of the following histologic types:
* Follicular large B-cell lymphoma (follicular, grade 3)
* Follicular mixed cell lymphoma (follicular, grade 2)
* Diffuse mixed cell lymphoma
* Diffuse large B-cell lymphoma
* Immunoblastic lymphoma
* Burkitt or Burkitt-like lymphoma
* Anaplastic large cell lymphoma
* Primary effusion lymphoma
* All stages eligible
* Seropositive for HIV by any approved test or positive HIV-1 RNA in plasma at anytime in the past
* Prior documentation of HIV seropositivity allowed
* Received 1 prior anthracycline-based regimen of curative intent
* No more than 1 prior regimen
* Measurable or evaluable disease
* Evaluable disease defined as not having bidimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests, such as gallium scan, positron emission tomography (PET) imaging and/or bone marrow biopsy
* No primary CNS lymphoma
* Lymphomatous meningitis or brain metastasis eligible provided other measurable systemic lymphomatous disease is also present
* Less than 25% bone marrow involvement with lymphoma
* Concurrent effective highly active anti-retroviral therapy (HAART) required at study entry
* HIV viral load \< 100,000 copies/mL if HAART was not used previously
PATIENT CHARACTERISTICS:
* Karnofsky performance status 50-100%
* Bilirubin ≤ 2.0 mg/dL (unless elevated due to lymphom…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.